Market Overview

The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More

Share:
The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results.

Here's a look at the upcoming week's catalytic events.

Conferences

  • 25th Annual Congress on Cardiology and Medical Interventions: July 16-17, Atlanta, Georgia
  • 2nd International Conference on Medical and Clinical Microbiology: July 16-17, Melbourne, Australia
  • 25th World Congress on Neurology and Neurodisorders: July 16-17, Melbourne, Australia
  • 8th World Congress on Breast Cancer & Therapies: July 16-17, Melbourne, Australia
  • 2nd World Congress on Radiology and Oncology: July 16-17, Dubai
  • Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here

  • 7th World Congress on Addictive Disorders & Addiction Therapy: July 16-18, London
  • 29th International Conference on Public Mental Health and Neuroscience: July 16-18, Dubai
  • 4th Annual Conference on Preventive Oncology: July 18-19, Atlanta, Georgia
  • 4th Annual Conference on Gynecologic Oncology, Reproductive Disorders, Maternal-Fetal Medicine & Obstetrics: July 18-19, Atlanta, Georgia
  • 11th World Congress on Orthopedics, Rheumatology & Sports Medicine: July 18-19, Sydney, Australia
  • 64th Annual International Society on Thrombosis and Haemostasis  Scientific and Standardization Committee Meeting: July 18-21, Dublin, Ireland

Clinical Trial Results

Catalyst Biosciences Inc (NASDAQ: CBIO) is set to release interim Phase 2 data for its hemophilia treatment marzeptacog alfa at the ISTH SSC meeting Wednesday.

Earnings

Monday, July 16

Avid Bioservices Inc (NASDAQ: CDMO)

Thursday, July 19

Intuitive Surgical, Inc. (NASDAQ: ISRG)

See Also: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

IPO

Allakos, a clinical stage biotech company developing therapy for treating eosinophil and mast cell-related diseases, is set to offer 6 million shares with an expected price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol (NASDAQ: ALLK).

Constellation Pharmaceuticals will offer 5.34 million shares in an IPO with an estimated price range of $14-$15. The company, which develops therapies to tackle cancers associated with abnormal gene expression or drug resistance, seeks to list its shares on the Nasdaq under the ticker symbol (NASDAQ: CNST).

Crinetics Pharmaceuticals, which develops therapies for rare endocrine diseases and endocrine-related tumors, is planning a 5-million-share IPO, with the shares expected to be priced between $15 and $17. The shares will be listed on the Nasdaq under the ticker symbol (NASDAQ: CRNX).

Oncolytic immunotherapy company Replimune Group is due to offer 6.7 million shares in an IPO, with the price estimated in a range of $14-$16. The shares are to be listed on the Nasdaq under the ticker symbol (NASDAQ: REPL).

Rubius Therapeutics is set to offer 9.53 million shares in an IPO expected to be priced between $20 and $22. The company is looking to list its shares on the Nasdaq under the ticker symbol (NASDAQ: RUBY).

IPO Quiet Period Expirations

  • Eidos Therapeutics Inc (NASDAQ: EIDX)
  • Kezar Life Sciences Inc (NASDAQ: KZR)
  • Aptinyx Inc (NASDAQ: APTX)
  • Xeris Pharmaceuticals Inc (NASDAQ: XERS)
  • Magenta Therapeutics Inc (NASDAQ: MGTA)
  • Avrobio Inc (NASDAQ: AVRO)
  • Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL)

Posted-In: Biotech Earnings News Previews FDA IPOs Top Stories Trading Ideas Best of Benzinga

 

Related Articles (APTX + ALLK)

View Comments and Join the Discussion!

Medical Marijuana Sales Decline Continues In Colorado As Recreational Weed Disrupts Market

Supreme Court Nominee Brett Kavanaugh: What You Need To Know